These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 7021355)

  • 1. Marrow transplantation in acute leukemia following busulfan and cyclophosphamide.
    Tutschka PJ; Santos GW; Elfenbein GJ
    Haematol Blood Transfus; 1980; 25():375-80. PubMed ID: 7021355
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of cyclosporin A (CsA) in a rat model of allogeneic marrow transplantation.
    Tutschka PJ; Beschorner WE; Hess AD
    Haematol Blood Transfus; 1980; 25():241-53. PubMed ID: 7021342
    [No Abstract]   [Full Text] [Related]  

  • 3. Busulfan (Bu) and cyclophosphamide (Cy) for marrow transplantation.
    Santos GW
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():236-9. PubMed ID: 2653511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide.
    Galimberti M; Polchi P; Lucarelli G; Angelucci E; Baronciani D; Giardini C; Gaziev D; Erer B; Ripalti M; Rapa S
    Bone Marrow Transplant; 1994 Feb; 13(2):197-201. PubMed ID: 8205089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow transplantation in the busulfin-treated rat. III. Relationship between myelosuppression and immunosuppression for conditioning bone marrow recipients.
    Tutschka PJ; Santon GW
    Transplantation; 1977 Jul; 24(1):52-62. PubMed ID: 18820
    [No Abstract]   [Full Text] [Related]  

  • 7. A randomized trial comparing busulfan vs total body irradiation in allogeneic marrow transplant recipients with hematological malignancies.
    Ringdén O; Ruutu T; Remberger M; Nikoskelainen J; Volin L; Vindeløv L; Parkkali T; Lenhoff S; Sallerfors B; Ljungman P
    Transplant Proc; 1994 Jun; 26(3):1831-2. PubMed ID: 8030160
    [No Abstract]   [Full Text] [Related]  

  • 8. Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2).
    Copelan EA; Biggs JC; Szer J; Thompson JM; Crilley P; Brodsky I; Klein JL; Kapoor N; Harman GS; Avalos BR
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):33-8; quiz 39. PubMed ID: 8342074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of graft-versus-host reactivity, lymphocyte depletion, and cell dose on allogeneic bone marrow engraftment.
    Glass B; Uharek L; Gaska T; Gassmann W; Löffler H; Müller-Ruchholtz W
    Bone Marrow Transplant; 1993; 12 Suppl 3():S41-7. PubMed ID: 8124257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintaining high levels of syngeneic bone marrow engraftment while omitting cyclophosphamide in busulfan-containing conditioning regimens.
    Robbin Westerhof G; Ploemacher RE; Down JD
    Blood; 1998 Aug; 92(4):1462-3. PubMed ID: 9694742
    [No Abstract]   [Full Text] [Related]  

  • 11. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
    Ringdén O; Labopin M; Tura S; Arcese W; Iriondo A; Zittoun R; Sierra J; Gorin NC
    Br J Haematol; 1996 Jun; 93(3):637-45. PubMed ID: 8652385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.
    van Besien K; Thall P; Korbling M; Pugh WC; Khouri I; Mehra R; Giralt S; Anderlini P; Amin K; Mirza N; Seong D; Gajewski J; Hester J; Andersson B; Cabanillas F; Champlin R; Przepiorka D
    Biol Blood Marrow Transplant; 1997 Aug; 3(3):150-6. PubMed ID: 9310192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy.
    Klein JL; Avalos BR; Belt P; Taylor CA; Ezzone SA; Scholl MD; Fisher J; Young D; Copelan EA
    Bone Marrow Transplant; 1996 Apr; 17(4):479-83. PubMed ID: 8722342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow transplantation in acute nonlymphoblastic leukemia.
    Zwaan FE; Jansen J
    Semin Hematol; 1984 Jan; 21(1):36-42. PubMed ID: 6367055
    [No Abstract]   [Full Text] [Related]  

  • 15. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide.
    Santos GW; Tutschka PJ; Brookmeyer R; Saral R; Beschorner WE; Bias WB; Braine HG; Burns WH; Elfenbein GJ; Kaizer H
    N Engl J Med; 1983 Dec; 309(22):1347-53. PubMed ID: 6355849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marrow transplantation following busulfan and cyclophosphamide as treatment for translocation (4;11) acute leukaemia.
    Copelan EA; Kapoor N; Murcek M; Theil K; Tutschka PJ
    Br J Haematol; 1988 Sep; 70(1):127-8. PubMed ID: 3052567
    [No Abstract]   [Full Text] [Related]  

  • 17. Ifosfamide and ACNU in experimental allogeneic bone marrow transplantation.
    Gassmann W; Erbersdobler A; Uharek L; Glass B; Löffler H; Mueller-Ruchholtz W
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S224-7. PubMed ID: 1795012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morbidity and non-relapse mortality after allogeneic bone marrow transplantation in adult leukemia patients conditioned with busulfan plus cyclophosphamide: a retrospective comparison of oral versus intravenous busulfan.
    Kim SE; Lee JH; Choi SJ; Lee JH; Ryu SG; Lee KH
    Haematologica; 2005 Feb; 90(2):285-6. PubMed ID: 15710597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of graft failure by cyclosporine in rats receiving lymphocyte-depleted MHC-mismatched bone marrow.
    Wagner JE
    Transplantation; 1992 Mar; 53(3):624-8. PubMed ID: 1549856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of infant leukemia with busulfan, cyclophosphamide +/- etoposide and bone marrow transplantation.
    Emminger W; Emminger-Schmidmeier W; Haas OA; Urban C; Ambros P; Peters C; Mann G; Fink FM; Ferstl G; Höcker P
    Bone Marrow Transplant; 1992 May; 9(5):313-8. PubMed ID: 1617314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.